Proactive Investors - Run By Investors For Investors

Summit Therapeutics shares DMD data

One poster at an industry conference this week will include validation data of muscle biopsy biomarkers used to assess utrophin modulator activity
Summit Therapeutics shares DMD data
Duchenne Muscular Dystrophy is a muscle wasting disease that affects boys

Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) said it and its collaboration partners will be presenting information related to its phase II clinical trial.

One poster at an industry conference this week will include validation data of muscle biopsy biomarkers used to assess utrophin modulator activity.

Utrophin control is central to Summit drug ezutromid, which is a potential treatment for boys with the incurable muscle wasting disease, Duchenne Muscular Dystrophy (DMD).

Flagship collaboration 

The biomarker breakthrough has come out of Summit’s collaboration with Flagship Biosciences.

"Developing new biomarkers capable of more reliably analysing muscle biopsies in clinical trials has been a major priority for Summit, and I am delighted with the progress made in our collaboration with Flagship,” said Dr David Roblin, the company’s chief medical officer.

“These automated techniques are capable of analysing thousands of muscle fibres in whole muscle biopsy sections, and we believe that their use could help us establish proof of mechanism for our utrophin modulator, ezutromid, in our ongoing PhaseOut DMD clinical trial."

The AIM and NASDAQ-listed life sciences company will also share baseline characteristics of patients enrolled into Summit's ongoing PhaseOut DMD study.

The conference, the 22nd International Congress of the World Muscle Society, is currently taking place in Saint-Malo, France.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
Hep C
November 22 2018
The company made positive operational progress in the year to June 30.
1538160791_petri-dishes.jpg
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use